Fig. 2

Kaplan–Meier estimates for factors affecting time between CNS-metastasis diagnosis and BC-LMD diagnosis. A Patients with TNBC experienced a significantly shorter median time between breast cancer CNS-metastasis diagnosis and BC-LMD (4.3 months) compared to HR + (9.1 months) and HER2 + (10.5 months) patients. B Patients that received systemic therapy experienced a longer median time between CNS metastasis and BC-LMD (12.5 months) than patients who did not receive any systemic therapy (4.3 months). C Patients that received WBRT had a longer median time between their CNS metastasis and BC-LMD diagnosis (14.1 months) compared to patients that did not receive WBRT (5.3 months). HR + Hormone Receptor Positive; HER2 + Human Epidermal Growth Factor Receptor 2-Positive; TNBC Triple Negative Breast Cancer; LMD Leptomeningeal Disease; WBRT Whole Brain Radiation Therapy